Newman Dignan & Sheerar Inc. Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Newman Dignan & Sheerar Inc. decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 312 shares of the biopharmaceutical company’s stock after selling 60 shares during the quarter. Newman Dignan & Sheerar Inc.’s holdings in Regeneron Pharmaceuticals were worth $222,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Manchester Capital Management LLC raised its position in Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 18 shares during the last quarter. ABC Arbitrage SA purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $1,510,000. Klingenstein Fields & Co. LP raised its position in Regeneron Pharmaceuticals by 1,083.7% in the 4th quarter. Klingenstein Fields & Co. LP now owns 6,806 shares of the biopharmaceutical company’s stock worth $4,848,000 after buying an additional 6,231 shares during the last quarter. Banque Pictet & Cie SA purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $4,496,000. Finally, V Square Quantitative Management LLC raised its position in Regeneron Pharmaceuticals by 11.9% in the 4th quarter. V Square Quantitative Management LLC now owns 1,489 shares of the biopharmaceutical company’s stock worth $1,061,000 after buying an additional 158 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.1 %

NASDAQ REGN opened at $673.60 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73. The company has a market capitalization of $74.02 billion, a P/E ratio of 17.60, a P/E/G ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The stock has a 50 day moving average price of $706.92 and a 200-day moving average price of $897.42.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $11.86 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of recent analyst reports. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. TD Cowen reduced their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Finally, Bank of America reaffirmed an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.